United Therapeutics wins FDA approval for LungFX lung perfusion device

United Therapeutics Corporation

United Therapeutics Corporation

UTHR

0.00
  • United Therapeutics won FDA premarket approval for its LungFX device for centralized ex vivo lung perfusion of donor lungs.
  • The system targets organs that organ procurement groups cannot place using standard direct-to-recipient procedures.
  • Subsidiary Lung Bioengineering expects to add LungFX to its centralized EVLP services in 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202606290630BIZWIRE_USPR_____20260629_BW284898) on June 29, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.